BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Alnylam Joins Illumina and NashBio’s Alliance for Genomic Discovery

Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members levera...

September 19, 2025 | News

Mabwell and Aditum Bio Launch Kalexo Bio with $1 Billion siRNA Deal for Dyslipidemia and ASCVD

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio announced the launch of Kalexo Bio, a new company formed in conjunction with an exc...

September 18, 2025 | News

ProBioGen to Operate GMP Manufacturing Hub at Berlin’s New Gene and Cell Therapy Centre

ProBioGen and the Berlin Institute of Health at Charité (BIH) announced that ProBioGen has been selected to operate the process...

September 17, 2025 | News

Rona Therapeutics Submits RN3161 to Australian HREC as INHBE-Targeting GalNAc siRNA for Obesity

Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced the successful submission of RN3161 to the Australian Human R...

September 16, 2025 | News

Shineco Strikes $8.7M R&D Deal and Builds Global Bridge with Singapore’s BICC

Shineco Inc., a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, announced two major strategic advances. Its subs...

September 15, 2025 | News

YolTech Raises $45 Million in Series B Funding to Propel In Vivo Gene-Editing Therapies

YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $...

September 12, 2025 | News

PlasmidFactory’s Dr Martin Schleef Receives Germany’s Coveted NRW Innovation Prize

The founder and long-standing CEO of PlasmidFactory GmbH, Dr. Martin Schleef, was honored in Düsseldorf with the Innovation Award 2025 of the St...

September 11, 2025 | News

Andelyn Biosciences and Tern Therapeutics Partner to Advance Gene Therapy for CLN2 Batten Disease

Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered...

September 08, 2025 | News

Alphamab Oncology Reports Strong H1 2025 Growth and Pipeline Advancements, Achieving Profitability

Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2025 and highlighted recent business...

September 01, 2025 | Company results

Celaid and AGC Partner in Japan to Advance Scalable Expansion of iPSC-Derived Blood Stem Cells

Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem a...

August 29, 2025 | News

Hope Biosciences Receives First RMAT Designation For Stem Cell Therapy In Multiple Sclerosis

Leading U.S. stem cell banking and cellular therapeutic manufacturer Hope Biosciences announces the U.S. Food and Drug Administration (FDA) has g...

August 28, 2025 | News

Cartherics Secures Chinese Patent for Gene-Edited Immune Cell Therapy Targeting Solid Tumours

Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies f...

August 27, 2025 | News

iNtRON Bio Files Patents for Groundbreaking IMPA™ Gene-Editing Technology Targeting Pasteurella Bacteriophages

Development of gene-editing technology for Pasteurella bacteriophages using the IMPA™ platform Establishment of an advanced platform tec...

August 27, 2025 | News

Leads Biolabs Doses First Patient In Phase II Trial Of LBL-034, China’s First Potential GPRC5D-Targeted T-Cell Engager

Nanjing Leads Biolabs Co., Ltd. announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following...

August 26, 2025 | News

Stay Connected